

***Core indicators for monitoring the Ending the HIV Epidemic initiative
(preliminary data): National HIV Surveillance System data reported
through September 2021; and preexposure prophylaxis (PrEP) data reported
through June 2021***

Advisory Statement

Effective date: May 21, 2024

Publication date of referenced document: December 2021

Preexposure prophylaxis (PrEP) coverage is currently estimated by taking the number of persons prescribed PrEP (numerator) and dividing it by the estimated number of persons with indications for PrEP (denominator). Since the current methodology for estimating PrEP coverage was first published in 2018, CDC has cited limitations of both the numerator and denominator. For example, the number of persons prescribed PrEP is estimated by using data from the IQVIA pharmacy database based on an algorithm that includes FDA-approved drugs for PrEP. Although IQVIA records 94% of all prescriptions from retail pharmacies and 74% from mail-order outlets in the United States, data from closed health care systems are not included in the IQVIA data set. Therefore, the current PrEP numerator has represented minimum estimates of PrEP prescriptions. Additionally, race/ethnicity data in the IQVIA database are only available for <40% of persons prescribed PrEP each year. Regarding limitations of the current denominator, the number of persons who have indications for PrEP is estimated by using data from 3 sources: National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Each of these data sources have different schedules of data availability. As a result, the availability of a denominator often lags the availability of a numerator.

In March 2024, updated data from 2 closed-system sources were made available to CDC that can improve the representativeness of the number of persons prescribed PrEP in the United States. In the coming months, CDC also expects to have updates to the data sets currently used to estimate the number of persons with indications for PrEP. To ensure that PrEP coverage estimates are calculated using the best available data at the time of publication, CDC is pausing PrEP coverage reporting for one year. During this time, CDC will update PrEP coverage data sources and determine the best way to present PrEP coverage. CDC plans to resume PrEP coverage reporting in the next HIV Surveillance Supplemental (Monitoring) Report, currently scheduled for publication in June 2025.

Until updated estimates are published, CDC advises against citing specific PrEP coverage data points and instead recommends referencing general trends and disparities. In addition, because of a formula error that affects a subset of race and ethnicity PrEP data, race and ethnicity data points from all reports published prior to 2024 should not be cited.

HIV | SURVEILLANCE DATA TABLES

**Core Indicators for Monitoring the Ending the
HIV Epidemic Initiative (*Preliminary Data*):**

**National HIV Surveillance System Data Reported
through September 2021; and Preexposure
Prophylaxis (PrEP) Data Reported through June 2021**



Centers for Disease
Control and Prevention
National Center for HIV/AIDS,
Viral Hepatitis, STD, and
TB Prevention

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through September 2021 and preexposure prophylaxis (PrEP) data reported through June 2021.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through September 2021; and preexposure prophylaxis (PrEP) data reported through June 2021. *HIV Surveillance Data Tables* 2021;2(No. 5). <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>. Published December 2021. Accessed [date].

On the Web: <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>

Confidential information, referrals, and educational material on HIV infection

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Dawn Smith, Jianmin Li, Xiaohong Hu, Baohua Wu, Kyung Lee, Weiming Zhu, Lei Yu, and Norma Harris.

Michael Friend of the Office for Science and the Web and Consumer Services Team of the Prevention Communications Branch are acknowledged for editing and desktop publishing this report.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Technical Notes	4
References	6
Tables	
1a Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2020 through September 2021—United States (preliminary)	7
1b Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2020 through September 2021—United States and 6 dependent areas (preliminary)	8
1c Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2020 through September 2021—United States and 6 dependent areas (preliminary)	9
1d Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2020 through September 2021—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	10
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by selected characteristics, January 2020–June 2021—44 states and the District of Columbia (preliminary)	12
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2020–June 2021—44 states and the District of Columbia (preliminary)	14
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2020–June 2021—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	16
3a Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by selected characteristics—United States (preliminary)	18
3b Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary)	20
3c Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	23

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and then by at least 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf>.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care reported to CDC as of September 2021 for the years 2020 and 2021, and data on preexposure prophylaxis (PrEP) coverage for the years 2019, 2020, and 2021 (preliminary). Data for the 3 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated.

TABULATION AND PRESENTATION OF DATA

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥ 13 years with HIV diagnosed during January 2020 through September 2021 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2011–2015 diagnoses) found that, on average, approximately 75% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 95% of HIV diagnoses are reported to CDC by the end of the following year. Data reported to CDC’s National HIV Surveillance System (NHSS) are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing,

care-related services, and case surveillance activities in state/local jurisdictions [2].

More information on counting diagnoses of HIV infection can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/index.html> (*HIV Surveillance Report*, 2019).

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years whose infection was diagnosed during January 2020 through June 2021 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during January 2020 through June 2021 and who had ≥ 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during January 2020 through June 2021. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons whose HIV infection was diagnosed during January 2020 through June 2021 and was reported to NHSS through September 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions [2].

More information on calculating linkage to care can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-26-no-2/index.html> (*Monitoring selected national HIV prevention and care objectives*

by using HIV surveillance data—United States and 6 dependent areas, 2019).

Preexposure Prophylaxis Coverage

Preexposure prophylaxis (PrEP) coverage, reported as a percentage, is defined as the number of persons aged ≥ 16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥ 16 years who had indications for PrEP during the specified year (Tables 3a–3c). PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥ 16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 92% of all prescriptions from retail pharmacies and 60%–86% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [3–5]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Starting with the 2019 data, TAF/FTC was included in the algorithm to classify the number of persons prescribed PrEP. In addition, generic TDF/FTC for PrEP became available in the United States in October 2020. Starting with the 2020 data, generic TDF/FTC was included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not

available in the IQVIA database, and race/ethnicity data are available for $<40\%$ of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [6], and (b) the U.S. Department of Housing and Urban Development's ZIP Code Crosswalk Files [7]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP indications

The ACS and U.S. Census Bureau files were used to estimate the number of men who have sex with men (MSM) in a jurisdiction [8, 9]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [10].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [8]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the years 2019 through June 2021 by using the IQVIA data reported through

June 2021. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator by 1 year or more. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of *HIV Surveillance Data Tables*, 2018 denominators were used for 2019, 2020, and 2021 PrEP coverage data; consequently, 2019 through June 2021 PrEP coverage data are considered preliminary. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution and with an awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

More information on calculating PrEP coverage can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-26-no-2/index.html> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019*).

REFERENCES

1. HHS. What is *Ending the HIV Epidemic in the U.S.*? <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated June 2, 2021. Accessed December 1, 2021.
2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. *MMWR* 2020;69(18):551–556. doi:<http://dx.doi.org/10.15585/mmwr.mm6918e2>
3. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
4. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
5. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
6. U.S. Census Bureau. American Community Survey 5-year data (2009–2019). <https://www.census.gov/data/developers/data-sets/acs-5year.2019.html>. Published December 10, 2020. Accessed December 1, 2021.
7. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Updated June 2021. Accessed December 1, 2021.
8. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* 2016;2(1):e14.
9. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012;6:98–107.
10. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4

Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2020 through September 2021—United States (preliminary)

	2020 No.	2021 (January–September) No.
Gender		
Male	23,772	17,817
Female	5,307	3,985
Transgender woman ^a	610	431
Transgender man ^a	40	31
Additional gender identity ^b	15	20
Age at diagnosis (yr)		
13–24	5,982	4,242
25–34	11,059	8,238
35–44	5,783	4,671
45–54	3,843	2,769
≥ 55	3,077	2,364
Race/ethnicity		
American Indian/Alaska Native	190	144
Asian	607	426
Black/African American	12,677	9,302
Hispanic/Latino ^c	7,847	6,130
Native Hawaiian/other Pacific Islander	64	48
White	7,662	5,872
Multiracial	697	362
Transmission category^d		
Male-to-male sexual contact	20,272	15,228
Injection drug use		
Male	1,136	865
Female	830	647
Male-to-male sexual contact and injection drug use	1,057	805
Heterosexual contact ^e		
Male	1,908	1,347
Female	4,490	3,353
Other ^f		
Male	25	22
Female	27	18
Region of residence^g		
Northeast	4,203	2,882
Midwest	4,071	2,822
South	15,455	12,419
West	6,015	4,161
Total	29,744	22,284

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender.

“Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2020 through September 2021—United States and 6 dependent areas (*preliminary*)

	2020 No.	2021 (January–September) No.
Gender		
Male	24,020	18,014
Female	5,348	4,022
Transgender woman ^a	612	431
Transgender man ^a	40	31
Additional gender identity ^b	15	20
Age at diagnosis (yr)		
13–24	6,034	4,280
25–34	11,140	8,308
35–44	5,842	4,717
45–54	3,891	2,818
≥55	3,128	2,395
Race/ethnicity		
American Indian/Alaska Native	190	144
Asian	607	426
Black/African American	12,680	9,305
Hispanic/Latino ^c	8,135	6,357
Native Hawaiian/other Pacific Islander	64	48
White	7,662	5,876
Multiracial	697	362
Transmission category^d		
Male-to-male sexual contact	20,455	15,380
Injection drug use		
Male	1,156	876
Female	833	647
Male-to-male sexual contact and injection drug use	1,062	806
Heterosexual contact ^e		
Male	1,950	1,379
Female	4,529	3,390
Other ^f		
Male	25	22
Female	27	18
Region of residence^g		
Northeast	4,203	2,882
Midwest	4,071	2,822
South	15,455	12,419
West	6,015	4,161
U.S. dependent areas	291	234
Total	30,035	22,518

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender.

“Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 1c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2020 through September 2021—United States and 6 dependent areas (*preliminary*)

Area of residence	2020	2021
	No.	(January–September) No.
Alabama	586	314
Alaska	29	13
Arizona	668	505
Arkansas	244	264
California	3,636	2,308
Colorado	326	256
Connecticut	171	136
Delaware	95	55
District of Columbia	198	64
Florida	3,424	3,463
Georgia	1,833	1,218
Hawaii	50	41
Idaho	32	24
Illinois	1,055	533
Indiana	434	329
Iowa	100	81
Kansas	138	112
Kentucky	301	269
Louisiana	725	663
Maine	16	25
Maryland	708	506
Massachusetts	431	157
Michigan	521	460
Minnesota	226	203
Mississippi	401	275
Missouri	359	367
Montana	15	9
Nebraska	73	62
Nevada	391	359
New Hampshire	29	22
New Jersey	763	601
New Mexico	123	93
New York	1,958	1,243
North Carolina	1,077	966
North Dakota	36	15
Ohio	885	484
Oklahoma	235	163
Oregon	181	130
Pennsylvania	773	661
Rhode Island	53	33
South Carolina	679	446
South Dakota	34	16
Tennessee	642	560
Texas	3,553	2,539
Utah	129	85
Vermont	9	4
Virginia	625	563
Washington	421	335
West Virginia	129	91
Wisconsin	210	160
Wyoming	14	3
Subtotal	29,744	22,284
U.S. dependent areas		
American Samoa	0	0
Guam	0	1
Northern Mariana Islands	0	0
Puerto Rico	288	230
Republic of Palau	0	0
U.S. Virgin Islands	3	3
Subtotal	291	234
Total	30,035	22,518

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2020 through September 2021—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	2020 No.	2021 (January–September) No.
Arizona		
Maricopa County	482	341
California		
Alameda County	151	121
Los Angeles County	1,306	783
Orange County	263	195
Riverside County	231	155
Sacramento County	68	43
San Bernardino County	259	164
San Diego County	275	107
San Francisco County	152	128
District of Columbia	198	64
Florida		
Broward County	460	510
Duval County	230	221
Hillsborough County	249	233
Miami-Dade County	811	899
Orange County	375	367
Palm Beach County	216	170
Pinellas County	154	110
Georgia		
Cobb County	122	75
DeKalb County	242	177
Fulton County	477	342
Gwinnett County	135	76
Illinois		
Cook County	758	397
Indiana		
Marion County	166	143
Louisiana		
East Baton Rouge Parish	124	109
Orleans Parish	106	104
Maryland		
Baltimore City	176	94
Montgomery County	80	68
Prince George's County	214	165
Massachusetts		
Suffolk County	133	59
Michigan		
Wayne County	228	184
Nevada		
Clark County	340	322
New Jersey		
Essex County	191	145
Hudson County	117	79

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2020 through September 2021—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	2020 No.	2021 (January–September) No.
New York		
Bronx County	341	243
Kings County	442	246
New York County	296	199
Queens County	315	177
North Carolina		
Mecklenburg County	209	207
Ohio		
Cuyahoga County	186	105
Franklin County	203	117
Hamilton County	133	55
Pennsylvania		
Philadelphia County	327	214
Puerto Rico		
San Juan Municipio	73	56
Tennessee		
Shelby County	232	199
Texas		
Bexar County	286	209
Dallas County	661	491
Harris County	913	716
Tarrant County	294	209
Travis County	165	146
Washington		
King County	199	159

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/ local jurisdictions.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2020–June 2021—44 states and the District of Columbia (preliminary)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2020				
Gender					
Male	22,181	18,317	82.6	3,864	17.4
Female	4,925	4,060	82.4	865	17.6
Transgender woman ^a	572	465	81.3	107	18.7
Transgender man ^a	37	33	89.2	4	10.8
Additional gender identity ^b	13	12	92.3	1	7.7
Age at diagnosis (yr)					
13–24	5,606	4,494	80.2	1,112	19.8
25–34	10,329	8,515	82.4	1,814	17.6
35–44	5,390	4,452	82.6	938	17.4
45–54	3,548	3,007	84.8	541	15.2
≥55	2,855	2,419	84.7	436	15.3
Race/ethnicity					
American Indian/Alaska Native	185	150	81.1	35	18.9
Asian	582	512	88.0	70	12.0
Black/African American	11,889	9,481	79.7	2,408	20.3
Hispanic/Latino ^c	7,343	6,270	85.4	1,073	14.6
Native Hawaiian/other Pacific Islander	63	54	85.7	9	14.3
White	7,034	5,887	83.7	1,147	16.3
Multiracial	632	533	84.3	99	15.7
Transmission category^d					
Male-to-male sexual contact	19,049	15,814	83.0	3,235	17.0
Injection drug use					
Male	1,001	781	78.0	220	22.0
Female	771	605	78.5	166	21.5
Male-to-male sexual contact and injection drug use	967	777	80.3	191	19.7
Heterosexual contact ^e					
Male	1,727	1,403	81.2	324	18.8
Female	4,166	3,465	83.2	700	16.8
Total^f	27,728	22,887	82.5	4,841	17.5

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2020–June 2021—44 states and the District of Columbia (preliminary) (cont)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2021 (January–June)				
Gender					
Male	12,531	10,361	82.7	2,170	17.3
Female	2,735	2,233	81.6	502	18.4
Transgender woman ^a	313	263	84.0	50	16.0
Transgender man ^a	26	23	88.5	3	11.5
Additional gender identity ^b	13	12	92.3	1	7.7
Age at diagnosis (yr)					
13–24	3,064	2,450	80.0	614	20.0
25–34	5,781	4,748	82.1	1,033	17.9
35–44	3,255	2,713	83.3	542	16.7
45–54	1,919	1,624	84.6	295	15.4
≥55	1,599	1,357	84.9	242	15.1
Race/ethnicity					
American Indian/Alaska Native	112	92	82.1	20	17.9
Asian	308	275	89.3	33	10.7
Black/African American	6,602	5,315	80.5	1,287	19.5
Hispanic/Latino ^c	4,298	3,631	84.5	667	15.5
Native Hawaiian/other Pacific Islander	38	30	78.9	8	21.1
White	4,011	3,339	83.2	672	16.8
Multiracial	249	210	84.3	39	15.7
Transmission category^d					
Male-to-male sexual contact	10,822	8,991	83.1	1,832	16.9
Injection drug use					
Male	565	425	75.1	140	24.9
Female	429	343	80.0	86	20.0
Male-to-male sexual contact and injection drug use	548	443	80.8	105	19.2
Heterosexual contact ^e					
Male	905	763	84.4	141	15.6
Female	2,320	1,903	82.0	417	18.0
Total^f	15,618	12,892	82.5	2,726	17.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through September 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2020 through June 2021 and reported to CDC through September 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

^f Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–June 2021—44 states and the District of Columbia (*preliminary*)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2020				
Alabama	586	468	79.9	118	20.1
Alaska	29	28	96.6	1	3.4
Arizona	668	566	84.7	102	15.3
Arkansas	244	198	81.1	46	18.9
California	3,636	3,035	83.5	601	16.5
Colorado	326	285	87.4	41	12.6
Connecticut	171	144	84.2	27	15.8
Delaware	95	76	80.0	19	20.0
District of Columbia	198	173	87.4	25	12.6
Florida	3,424	2,879	84.1	545	15.9
Georgia	1,833	1,508	82.3	325	17.7
Hawaii	50	43	86.0	7	14.0
Illinois	1,055	888	84.2	167	15.8
Indiana	434	321	74.0	113	26.0
Iowa	100	90	90.0	10	10.0
Louisiana	725	551	76.0	174	24.0
Maine	16	15	93.8	1	6.3
Maryland	708	619	87.4	89	12.6
Massachusetts	431	376	87.2	55	12.8
Michigan	521	440	84.5	81	15.5
Minnesota	226	199	88.1	27	11.9
Mississippi	401	292	72.8	109	27.2
Missouri	359	286	79.7	73	20.3
Montana	15	13	86.7	2	13.3
Nebraska	73	65	89.0	8	11.0
Nevada	391	336	85.9	55	14.1
New Hampshire	29	23	79.3	6	20.7
New Mexico	123	105	85.4	18	14.6
New York	1,958	1,687	86.2	271	13.8
North Carolina	1,077	886	82.3	191	17.7
North Dakota	36	31	86.1	5	13.9
Ohio	885	758	85.6	127	14.4
Oklahoma	235	182	77.4	53	22.6
Oregon	181	151	83.4	30	16.6
Rhode Island	53	48	90.6	5	9.4
South Carolina	679	598	88.1	81	11.9
South Dakota	34	30	88.2	4	11.8
Tennessee	642	477	74.3	165	25.7
Texas	3,553	2,735	77.0	818	23.0
Utah	129	109	84.5	20	15.5
Virginia	625	511	81.8	114	18.2
Washington	421	373	88.6	48	11.4
West Virginia	129	94	72.9	35	27.1
Wisconsin	210	182	86.7	28	13.3
Wyoming	14	13	92.9	1	7.1
Total	27,728	22,887	82.5	4,841	17.5

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–June 2021—44 states and the District of Columbia (*preliminary*) (*cont*)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2021 (January–June)				
Alabama	286	221	77.3	65	22.7
Alaska	10	10	100	0	0.0
Arizona	417	355	85.1	62	14.9
Arkansas	181	135	74.6	46	25.4
California	1,805	1,521	84.3	284	15.7
Colorado	186	161	86.6	25	13.4
Connecticut	107	95	88.8	12	11.2
Delaware	44	38	86.4	6	13.6
District of Columbia	56	49	87.5	7	12.5
Florida	2,344	2,004	85.5	340	14.5
Georgia	1,020	875	85.8	145	14.2
Hawaii	30	23	76.7	7	23.3
Illinois	453	397	87.6	56	12.4
Indiana	252	202	80.2	50	19.8
Iowa	59	54	91.5	5	8.5
Louisiana	494	403	81.6	91	18.4
Maine	17	14	82.4	3	17.6
Maryland	382	338	88.5	44	11.5
Massachusetts	137	130	94.9	7	5.1
Michigan	296	261	88.2	35	11.8
Minnesota	152	126	82.9	26	17.1
Mississippi	209	151	72.2	58	27.8
Missouri	259	200	77.2	59	22.8
Montana	8	8	100	0	0.0
Nebraska	51	43	84.3	8	15.7
Nevada	253	229	90.5	24	9.5
New Hampshire	19	19	100	0	0.0
New Mexico	71	63	88.7	8	11.3
New York	991	861	86.9	130	13.1
North Carolina	696	569	81.8	127	18.2
North Dakota	15	12	80.0	3	20.0
Ohio	419	363	86.6	56	13.4
Oklahoma	121	86	71.1	35	28.9
Oregon	98	80	81.6	18	18.4
Rhode Island	30	9	30.0	21	70.0
South Carolina	381	347	91.1	34	8.9
South Dakota	15	12	80.0	3	20.0
Tennessee	381	254	66.7	127	33.3
Texas	1,979	1,410	71.2	569	28.8
Utah	65	58	89.2	7	10.8
Virginia	423	354	83.7	69	16.3
Washington	224	201	89.7	23	10.3
West Virginia	65	45	69.2	20	30.8
Wisconsin	115	104	90.4	11	9.6
Wyoming	2	2	100	0	0.0
Total	15,618	12,892	82.5	2,726	17.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through September 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2020 through June 2021 and reported to CDC through September 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–June 2021—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	2020					2021 (January–June)				
	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
Arizona										
Maricopa County	482	412	85.5	70	14.5	274	235	85.8	39	14.2
California										
Alameda County	151	128	84.8	23	15.2	83	75	90.4	8	9.6
Los Angeles County	1,306	1,079	82.6	227	17.4	628	536	85.4	92	14.6
Orange County	263	236	89.7	27	10.3	137	119	86.9	18	13.1
Riverside County	231	189	81.8	42	18.2	112	84	75.0	28	25.0
Sacramento County	68	58	85.3	10	14.7	41	37	90.2	4	9.8
San Bernardino County	259	182	70.3	77	29.7	139	102	73.4	37	26.6
San Diego County	275	238	86.5	37	13.5	105	91	86.7	14	13.3
San Francisco County	152	144	94.7	8	5.3	87	81	93.1	6	6.9
District of Columbia	198	173	87.4	25	12.6	56	49	87.5	7	12.5
Florida										
Broward County	460	401	87.2	59	12.8	339	295	87.0	44	13.0
Duval County	230	185	80.4	45	19.6	151	120	79.5	31	20.5
Hillsborough County	249	211	84.7	38	15.3	161	138	85.7	23	14.3
Miami-Dade County	811	679	83.7	132	16.3	607	531	87.5	76	12.5
Orange County	375	323	86.1	52	13.9	240	198	82.5	42	17.5
Palm Beach County	216	173	80.1	43	19.9	154	126	81.8	28	18.2
Pinellas County	154	130	84.4	24	15.6	74	61	82.4	13	17.6
Georgia										
Cobb County	122	103	84.4	19	15.6	63	56	88.9	7	11.1
DeKalb County	242	200	82.6	42	17.4	152	136	89.5	16	10.5
Fulton County	477	402	84.3	75	15.7	282	241	85.5	41	14.5
Gwinnett County	135	105	77.8	30	22.2	66	59	89.4	7	10.6
Illinois										
Cook County	758	644	85.0	114	15.0	334	294	88.0	40	12.0
Indiana										
Marion County	166	127	76.5	39	23.5	112	88	78.6	24	21.4
Louisiana										
East Baton Rouge Parish	124	100	80.6	24	19.4	85	65	76.5	20	23.5
Orleans Parish	106	85	80.2	21	19.8	74	67	90.5	7	9.5
Maryland										
Baltimore City	176	152	86.4	24	13.6	77	70	90.9	7	9.1
Montgomery County	80	70	87.5	10	12.5	52	48	92.3	4	7.7
Prince George's County	214	193	90.2	21	9.8	130	109	83.8	21	16.2

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–June 2021—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	2020					2021 (January–June)				
	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
Massachusetts										
Suffolk County	133	119	89.5	14	10.5	52	50	96.2	2	3.8
Michigan										
Wayne County	228	188	82.5	40	17.5	120	103	85.8	17	14.2
Nevada										
Clark County	340	292	85.9	48	14.1	227	205	90.3	22	9.7
New York										
Bronx County	341	292	85.6	49	14.4	184	162	88.0	22	12.0
Kings County	442	376	85.1	66	14.9	202	173	85.6	29	14.4
New York County	296	255	86.1	41	13.9	153	126	82.4	27	17.6
Queens County	315	279	88.6	36	11.4	146	131	89.7	15	10.3
North Carolina										
Mecklenburg County	209	173	82.8	36	17.2	149	128	85.9	21	14.1
Ohio										
Cuyahoga County	186	166	89.2	20	10.8	88	80	90.9	8	9.1
Franklin County	203	179	88.2	24	11.8	91	80	87.9	11	12.1
Hamilton County	133	115	86.5	18	13.5	55	50	90.9	5	9.1
Pennsylvania										
Philadelphia County	327	281	85.9	46	14.1	140	115	82.1	25	17.9
Tennessee										
Shelby County	232	155	66.8	77	33.2	134	72	53.7	62	46.3
Texas										
Bexar County	286	204	71.3	82	28.7	172	125	72.7	47	27.3
Dallas County	661	500	75.6	161	24.4	357	266	74.5	91	25.5
Harris County	913	691	75.7	222	24.3	548	380	69.3	168	30.7
Tarrant County	294	214	72.8	80	27.2	167	87	52.1	80	47.9
Travis County	165	133	80.6	32	19.4	100	79	79.0	21	21.0
Washington										
King County	199	179	89.9	20	10.1	97	88	90.7	9	9.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through September 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2020 through June 2021 and reported to CDC through September 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by selected characteristics—United States (*preliminary*)

	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2019		
Sex at birth			
Male	252,268	989,200	25.5
Female	21,002	227,010	9.3
Age (yr)			
16–24	36,865	246,290	15.0
25–34	112,042	434,680	25.8
35–44	63,316	238,470	26.6
45–54	36,927	173,420	21.3
≥55	24,179	123,350	19.6
Race/ethnicity^d			
Black/African American	36,905	468,540	7.9
Hispanic/Latino ^e	43,045	312,820	13.8
Other	11,483	131,180	8.8
White	181,981	300,650	60.5
Total	273,414	1,216,210	22.5
	2020		
Sex at birth			
Male	276,978	989,200	28.0
Female	23,675	227,010	10.4
Age (yr)			
16–24	38,434	246,290	15.6
25–34	119,177	434,680	27.4
35–44	72,086	238,470	30.2
45–54	40,646	173,420	23.4
≥55	30,343	123,350	24.6
Race/ethnicity^d			
Black/African American	42,336	468,540	9.0
Hispanic/Latino ^e	48,958	312,820	15.7
Other	12,184	131,180	9.3
White	197,305	300,650	65.6
Total	300,783	1,216,210	24.7

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by selected characteristics—United States (*preliminary*) (*cont*)

	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2021 (January–June)		
Sex at birth			
Male	240,158	989,200	24.3
Female	17,102	227,010	7.5
Age (yr)			
16–24	27,624	246,290	11.2
25–34	101,205	434,680	23.3
35–44	65,637	238,470	27.5
45–54	35,022	173,420	20.2
≥55	27,981	123,350	22.7
Race/ethnicity^d			
Black/African American	35,316	468,540	7.5
Hispanic/Latino ^e	42,164	312,820	13.5
Other	10,340	131,180	7.9
White	169,732	300,650	56.5
Total	257,552	1,216,210	21.2

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. For this release, 2019 through June 2021 PrEP coverage data are considered preliminary. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through June 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019, 2020, and January–June 2021 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

^e Hispanic/Latino persons can be of any race.

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2019		
Alabama	1,837	11,020	16.7
Alaska	231	1,780	13.0
Arizona	4,547	25,780	17.6
Arkansas	739	5,130	14.4
California	41,466	165,030	25.1
Colorado	4,331	25,120	17.2
Connecticut	2,660	9,560	27.8
Delaware	474	4,400	10.8
District of Columbia	5,801	12,950	44.8
Florida	21,684	125,330	17.3
Georgia	8,586	39,030	22.0
Hawaii	812	4,360	18.6
Idaho	471	4,790	9.8
Illinois	16,567	55,860	29.7
Indiana	2,963	22,170	13.4
Iowa	1,420	4,760	29.8
Kansas	905	5,060	17.9
Kentucky	1,613	12,990	12.4
Louisiana	3,922	15,920	24.6
Maine	639	3,950	16.2
Maryland	4,938	27,300	18.1
Massachusetts	9,280	24,900	37.3
Michigan	4,364	29,570	14.8
Minnesota	4,184	21,720	19.3
Mississippi	938	4,530	20.7
Missouri	3,474	18,370	18.9
Montana	267	2,290	11.7
Nebraska	614	2,180	28.2
Nevada	2,161	11,390	19.0
New Hampshire	620	3,020	20.5
New Jersey	5,662	25,280	22.4
New Mexico	1,075	6,800	15.8
New York	34,998	72,640	48.2
North Carolina	5,369	32,490	16.5
North Dakota	193	1,520	12.7
Ohio	6,104	40,320	15.1
Oklahoma	1,141	11,030	10.3
Oregon	3,365	19,750	17.0
Pennsylvania	10,113	36,490	27.7
Puerto Rico	330	9,700	3.4
Rhode Island	1,082	3,880	27.9
South Carolina	1,728	10,390	16.6
South Dakota	148	910	16.3
Tennessee	3,886	22,460	17.3
Texas	22,977	123,790	18.6
Utah	2,024	6,840	29.6
Vermont	337	1,060	31.8
Virginia	4,399	31,430	14.0
Washington	9,817	40,050	24.5
West Virginia	570	5,250	10.9
Wisconsin	2,464	12,980	19.0
Wyoming	94	890	10.6

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2020		
Alabama	1,922	11,020	17.4
Alaska	245	1,780	13.8
Arizona	5,051	25,780	19.6
Arkansas	874	5,130	17.0
California	42,336	165,030	25.7
Colorado	4,754	25,120	18.9
Connecticut	2,474	9,560	25.9
Delaware	464	4,400	10.5
District of Columbia	5,945	12,950	45.9
Florida	34,594	125,330	27.6
Georgia	9,745	39,030	25.0
Hawaii	902	4,360	20.7
Idaho	656	4,790	13.7
Illinois	15,930	55,860	28.5
Indiana	3,204	22,170	14.5
Iowa	1,517	4,760	31.9
Kansas	950	5,060	18.8
Kentucky	1,670	12,990	12.9
Louisiana	3,608	15,920	22.7
Maine	663	3,950	16.8
Maryland	4,810	27,300	17.6
Massachusetts	9,375	24,900	37.7
Michigan	4,690	29,570	15.9
Minnesota	4,198	21,720	19.3
Mississippi	1,097	4,530	24.2
Missouri	3,585	18,370	19.5
Montana	300	2,290	13.1
Nebraska	725	2,180	33.3
Nevada	2,491	11,390	21.9
New Hampshire	652	3,020	21.6
New Jersey	5,928	25,280	23.4
New Mexico	1,239	6,800	18.2
New York	34,080	72,640	46.9
North Carolina	6,164	32,490	19.0
North Dakota	218	1,520	14.3
Ohio	6,834	40,320	16.9
Oklahoma	1,525	11,030	13.8
Oregon	3,817	19,750	19.3
Pennsylvania	10,610	36,490	29.1
Puerto Rico	368	9,700	3.8
Rhode Island	1,150	3,880	29.6
South Carolina	2,124	10,390	20.4
South Dakota	146	910	16.0
Tennessee	5,163	22,460	23.0
Texas	27,527	123,790	22.2
Utah	2,380	6,840	34.8
Vermont	321	1,060	30.3
Virginia	5,138	31,430	16.3
Washington	10,016	40,050	25.0
West Virginia	523	5,250	10.0
Wisconsin	2,526	12,980	19.5
Wyoming	99	890	11.1

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2021 (January–June)		
Alabama	1,921	11,020	17.4
Alaska	202	1,780	11.3
Arizona	4,583	25,780	17.8
Arkansas	874	5,130	17.0
California	35,454	165,030	21.5
Colorado	4,218	25,120	16.8
Connecticut	2,077	9,560	21.7
Delaware	431	4,400	9.8
District of Columbia	5,180	12,950	40.0
Florida	28,141	125,330	22.5
Georgia	8,865	39,030	22.7
Hawaii	789	4,360	18.1
Idaho	591	4,790	12.3
Illinois	13,599	55,860	24.3
Indiana	2,977	22,170	13.4
Iowa	1,291	4,760	27.1
Kansas	867	5,060	17.1
Kentucky	1,488	12,990	11.5
Louisiana	3,107	15,920	19.5
Maine	627	3,950	15.9
Maryland	4,119	27,300	15.1
Massachusetts	7,009	24,900	28.1
Michigan	4,213	29,570	14.2
Minnesota	3,672	21,720	16.9
Mississippi	1,158	4,530	25.6
Missouri	2,976	18,370	16.2
Montana	273	2,290	11.9
Nebraska	675	2,180	31.0
Nevada	2,663	11,390	23.4
New Hampshire	555	3,020	18.4
New Jersey	5,164	25,280	20.4
New Mexico	1,110	6,800	16.3
New York	27,971	72,640	38.5
North Carolina	5,583	32,490	17.2
North Dakota	184	1,520	12.1
Ohio	6,090	40,320	15.1
Oklahoma	1,571	11,030	14.2
Oregon	3,183	19,750	16.1
Pennsylvania	9,334	36,490	25.6
Puerto Rico	387	9,700	4.0
Rhode Island	1,097	3,880	28.3
South Carolina	2,080	10,390	20.0
South Dakota	143	910	15.7
Tennessee	5,108	22,460	22.7
Texas	25,331	123,790	20.5
Utah	2,336	6,840	34.2
Vermont	306	1,060	28.9
Virginia	4,257	31,430	13.5
Washington	8,085	40,050	20.2
West Virginia	501	5,250	9.5
Wisconsin	1,944	12,980	15.0
Wyoming	90	890	10.1

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. For this release, 2019 through June 2021 PrEP coverage data are considered preliminary. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through June 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019, 2020, and January–June 2021 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2019		
Arizona			
Maricopa County	3,519	22,720	15.5
California			
Alameda County	2,154	8,930	24.1
Los Angeles County	13,667	67,450	20.3
Orange County	2,030	10,510	19.3
Riverside County	1,762	11,080	15.9
Sacramento County	948	5,920	16.0
San Bernardino County	750	11,890	6.3
San Diego County	3,705	14,500	25.6
San Francisco County	8,788	10,840	81.1
District of Columbia	5,801	12,950	44.8
Florida			
Broward County	3,767	20,470	18.4
Duval County	503	8,970	5.6
Hillsborough County	1,377	12,910	10.7
Miami-Dade County	6,491	21,760	29.8
Orange County	2,765	15,310	18.1
Palm Beach County	876	9,170	9.6
Pinellas County	1,118	9,530	11.7
Georgia			
Cobb County	557	3,070	18.1
DeKalb County	1,550	6,290	24.6
Fulton County	3,272	13,120	24.9
Gwinnett County	676	3,240	20.9
Illinois			
Cook County	13,533	39,060	34.6
Indiana			
Marion County	1,120	9,150	12.2
Louisiana			
East Baton Rouge Parish	489	1,810	27.0
Orleans Parish	1,505	4,590	32.8
Maryland			
Baltimore City	897	6,330	14.2
Montgomery County	903	5,770	15.6
Prince George's County	810	4,040	20.0
Massachusetts			
Suffolk County	2,747	6,520	42.1
Michigan			
Wayne County	1,206	9,270	13.0
Nevada			
Clark County	1,849	11,670	15.8
New Jersey			
Essex County	680	4,090	16.6
Hudson County	1,041	4,650	22.4

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2019 (cont)		
New York			
Bronx County	2,214	5,570	39.7
Kings County	7,481	15,650	47.8
New York County	13,927	15,540	89.6
Queens County	3,848	9,230	41.7
North Carolina			
Mecklenburg County	1,341	8,450	15.9
Ohio			
Cuyahoga County	954	7,520	12.7
Franklin County	2,032	11,620	17.5
Hamilton County	555	7,720	7.2
Pennsylvania			
Philadelphia County	3,645	9,840	37.0
Puerto Rico			
San Juan Municipio	— ^d	2,190	n/a
Tennessee			
Shelby County	637	6,450	9.9
Texas			
Bexar County	1,492	11,920	12.5
Dallas County	4,048	28,670	14.1
Harris County	4,905	40,670	12.1
Tarrant County	1,451	11,340	12.8
Travis County	4,539	11,590	39.2
Washington			
King County	6,873	17,890	38.4

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2020		
Arizona			
Maricopa County	3,887	22,720	17.1
California			
Alameda County	2,025	8,930	22.7
Los Angeles County	14,797	67,450	21.9
Orange County	2,223	10,510	21.2
Riverside County	1,910	11,080	17.2
Sacramento County	969	5,920	16.4
San Bernardino County	817	11,890	6.9
San Diego County	3,774	14,500	26.0
San Francisco County	8,088	10,840	74.6
District of Columbia	5,945	12,950	45.9
Florida			
Broward County	6,711	20,470	32.8
Duval County	744	8,970	8.3
Hillsborough County	1,520	12,910	11.8
Miami-Dade County	10,272	21,760	47.2
Orange County	3,865	15,310	25.2
Palm Beach County	3,025	9,170	33.0
Pinellas County	1,214	9,530	12.7
Georgia			
Cobb County	644	3,070	21.0
DeKalb County	1,708	6,290	27.2
Fulton County	3,563	13,120	27.2
Gwinnett County	788	3,240	24.3
Illinois			
Cook County	12,842	39,060	32.9
Indiana			
Marion County	1,196	9,150	13.1
Louisiana			
East Baton Rouge Parish	524	1,810	29.0
Orleans Parish	1,340	4,590	29.2
Maryland			
Baltimore City	854	6,330	13.5
Montgomery County	910	5,770	15.8
Prince George's County	822	4,040	20.3
Massachusetts			
Suffolk County	2,801	6,520	43.0
Michigan			
Wayne County	1,228	9,270	13.2
Nevada			
Clark County	2,094	11,670	17.9
New Jersey			
Essex County	709	4,090	17.3
Hudson County	1,045	4,650	22.5

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2020 (cont)		
New York			
Bronx County	2,038	5,570	36.6
Kings County	7,401	15,650	47.3
New York County	13,648	15,540	87.8
Queens County	3,813	9,230	41.3
North Carolina			
Mecklenburg County	1,570	8,450	18.6
Ohio			
Cuyahoga County	961	7,520	12.8
Franklin County	2,307	11,620	19.9
Hamilton County	628	7,720	8.1
Pennsylvania			
Philadelphia County	3,485	9,840	35.4
Puerto Rico			
San Juan Municipio	— ^d	2,190	n/a
Tennessee			
Shelby County	809	6,450	12.5
Texas			
Bexar County	1,768	11,920	14.8
Dallas County	5,158	28,670	18.0
Harris County	5,973	40,670	14.7
Tarrant County	1,650	11,340	14.6
Travis County	5,063	11,590	43.7
Washington			
King County	6,969	17,890	39.0

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2021 (January–June)		
Arizona			
Maricopa County	3,547	22,720	15.6
California			
Alameda County	1,528	8,930	17.1
Los Angeles County	13,062	67,450	19.4
Orange County	1,993	10,510	19.0
Riverside County	1,770	11,080	16.0
Sacramento County	754	5,920	12.7
San Bernardino County	781	11,890	6.6
San Diego County	3,089	14,500	21.3
San Francisco County	6,074	10,840	56.0
District of Columbia	5,180	12,950	40.0
Florida			
Broward County	5,684	20,470	27.8
Duval County	629	8,970	7.0
Hillsborough County	1,353	12,910	10.5
Miami-Dade County	7,891	21,760	36.3
Orange County	3,385	15,310	22.1
Palm Beach County	1,778	9,170	19.4
Pinellas County	1,132	9,530	11.9
Georgia			
Cobb County	569	3,070	18.5
DeKalb County	1,546	6,290	24.6
Fulton County	3,236	13,120	24.7
Gwinnett County	705	3,240	21.8
Illinois			
Cook County	10,982	39,060	28.1
Indiana			
Marion County	1,149	9,150	12.6
Louisiana			
East Baton Rouge Parish	440	1,810	24.3
Orleans Parish	1,137	4,590	24.8
Maryland			
Baltimore City	707	6,330	11.2
Montgomery County	790	5,770	13.7
Prince George's County	734	4,040	18.2
Massachusetts			
Suffolk County	1,934	6,520	29.7
Michigan			
Wayne County	1,103	9,270	11.9
Nevada			
Clark County	2,288	11,670	19.6
New Jersey			
Essex County	592	4,090	14.5
Hudson County	896	4,650	19.3

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
	2021 (January–June) (<i>cont</i>)		
New York			
Bronx County	1,512	5,570	27.1
Kings County	6,253	15,650	40.0
New York County	11,558	15,540	74.4
Queens County	3,059	9,230	33.1
North Carolina			
Mecklenburg County	1,454	8,450	17.2
Ohio			
Cuyahoga County	884	7,520	11.8
Franklin County	2,056	11,620	17.7
Hamilton County	560	7,720	7.3
Pennsylvania			
Philadelphia County	2,872	9,840	29.2
Puerto Rico			
San Juan Municipio	— ^d	2,190	n/a
Tennessee			
Shelby County	691	6,450	10.7
Texas			
Bexar County	1,659	11,920	13.9
Dallas County	4,813	28,670	16.8
Harris County	5,566	40,670	13.7
Tarrant County	1,539	11,340	13.6
Travis County	4,406	11,590	38.0
Washington			
King County	5,590	17,890	31.2

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. For this release, 2019 through June 2021 PrEP coverage data are considered preliminary. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through June 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019, 2020, and January–June 2021 PrEP coverage data.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Data value <40 was not reported due to unreliability.